Motzer et al [1] recently reported results for a primary disease-free survival (DFS) analysis of the PROTECT phase 3 trial in which pazopanib (starting dose 800 mg subsequently reduced to 600 mg once daily owing to the high treatment discontinuation rate) failed to show a DFS benefit (primary endpoint) compared to placebo in the adjuvant setting. These results are in line with those obtained in ASSURE and more generally with other trials evaluating the role of angiogenesis inhibitors in different malignancies such as colon and breast cancer and melanoma.
Re: Robert J. Motzer, Alain Ravaud, Jean-Jacques Patard, et al. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.09.008 / Massari F, Di Nunno V, Ardizzoni A. - In: EUROPEAN UROLOGY. - ISSN 0302-2838. - STAMPA. - 8:(2017), pp. 72-73.
Re: Robert J. Motzer, Alain Ravaud, Jean-Jacques Patard, et al. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.09.008
Massari F;Di Nunno V;Ardizzoni A
2017
Abstract
Motzer et al [1] recently reported results for a primary disease-free survival (DFS) analysis of the PROTECT phase 3 trial in which pazopanib (starting dose 800 mg subsequently reduced to 600 mg once daily owing to the high treatment discontinuation rate) failed to show a DFS benefit (primary endpoint) compared to placebo in the adjuvant setting. These results are in line with those obtained in ASSURE and more generally with other trials evaluating the role of angiogenesis inhibitors in different malignancies such as colon and breast cancer and melanoma.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
